AT 193
Alternative Names: AT-193Latest Information Update: 17 Jun 2026
At a glance
- Originator Azora Therapeutics
- Developer ADial Pharmaceuticals
- Class Anti-inflammatories; Indoles; Skin disorder therapies; Small molecules
- Mechanism of Action Aryl hydrocarbon hydroxylase inhibitors; Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis
- No development reported Hidradenitis suppurativa; Psoriasis
Most Recent Events
- 11 Jun 2026 Azora Therapeutics has been acquired and merged into ADial Pharmaceuticals
- 28 Sep 2025 No recent reports of development identified for preclinical development in Hidradenitis suppurativa in USA (Topical)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Psoriasis in Australia (Topical)